Skip to content

"Glaucoma treatment using Ultrasound"

"Glaucoma treatment by cyclo-coagulation using High Intensity Focused Ultrasound (EyeOP medical device system) in Indian Patients"

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2014/05/004639
Enrollment
15
Registered
2014-05-29
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- Glaucoma

Interventions

Intervention1: Cyclo Coagulation using High Intensity Focused Ultrasound: EyeOP1 medical device is used for treatment of refractory glaucoma by decreasing the production of aqueous humor, thereby redu

Sponsors

EyeTechCare
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1.Primary Open Angle or Angle Closure Glaucoma and Secondary Glaucoma 2.Patient with no vision potential or blind eyes 3.No previous intraocular surgery or laser treatment during the 90 days before HIFU Day 4.Any patient with/without previous conventional glaucoma surgery failure 5.Angle closure glaucoma or narrow anatomical anterior chamber as identified by gonioscopy and classified as Shaffer Grade 0 or 1 6. Any patient with/without previous conventional glaucoma surgery failure

Exclusion criteria

Exclusion criteria: 1. Patient who has been diagnosed for normal tension glaucoma 2. Glaucoma drainage device implanted and still presented in the eye to be treated 3. Ocular or retrobulbar tumor 4. Ocular infection within 14 days prior to the HIFU procedure 5. Ocular disease other than glaucoma that may affect assessment of visual acuity and/or IOP

Design outcomes

Primary

MeasureTime frame
Reduction of Intraocular Pressure relative to the pre-operative value will be assessed at each follow-up visit with the final measurement of success at 3 months.Timepoint: Day 1, Day 7, Month 1, Month 2, Month 3

Secondary

MeasureTime frame
1) Efficacy parameters and success rate 2) Safety parametersTimepoint: 1.1) Mean IOP at each follow-up visit compared to baseline IOP 1.2) Mean IOP variation compared to the baseline at each follow-up visits 1.3) Number of ocular hypotensive medications at each follow-up visits 2.1) Rate of per-operative device and/or procedure-related Adverse Events 2.2) Rate of post-operative device and/or procedure-related complications and adverse events at each follow-up visit

Countries

India

Contacts

Public ContactNaresh Kumar Pagidimarry

Maxivision Super Speciality Eye Hospital

nilanjana_deb@hotmail.com91-9390148673

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026